RGD Reference Report - Polymorphisms in the promoter region of the basic fibroblast growth factor gene and proliferative diabetic retinopathy in Caucasians with type 2 diabetes. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Polymorphisms in the promoter region of the basic fibroblast growth factor gene and proliferative diabetic retinopathy in Caucasians with type 2 diabetes.

Authors: Petrovic, MG  Krkovic, M  Osredkar, J  Hawlina, M  Petrovic, D 
Citation: Petrovic MG, etal., Clin Experiment Ophthalmol. 2008 Mar;36(2):168-72. Epub 2008 Feb 13.
RGD ID: 2315844
Pubmed: PMID:18279437   (View Abstract at PubMed)
DOI: DOI:10.1111/j.1442-9071.2007.01647.x   (Journal Full-text)

BACKGROUND: Basic fibroblast growth factor (bFGF) expression is implicated in proliferative diabetic retinopathy (PDR). The aim of this study was to investigate the association of genetic polymorphisms (-553T/A, -834T/A and -921C/G) in the promoter region of the bFGF gene with PDR in patients with type 2 diabetes. The second aim was to determine whether serum levels of bFGF are affected by genetic factors. METHODS: In this cross-sectional case-control study 313 unrelated Caucasians (Slovene population) with type 2 diabetes mellitus were enrolled: 206 patients with PDR and the control group of 107 subjects with type 2 diabetes of duration of more than 10 years who had no clinical signs of diabetic retinopathy. We analysed serum bFGF levels in 78 subjects with type 2 diabetes and 25 subjects without diabetes. RESULTS: The AT genotype of the -553T/A polymorphism was present in 31 (15.0%) PDR patients and in seven (6.5%) controls (P = 0.03, odds ratio = 2.0, 95% confidence interval = 1.0-3.9). The AT genotype of the -834T/A polymorphism was present in 12 (5.8%) PDR patients and in 15 (14.0%) controls (P = 0.01, odds ratio = 0.4, 95% confidence interval = 0.2-0.8). Significantly higher bFGF serum levels were demonstrated in diabetics with the AT genotype of the -553 polymorphism compared with diabetics with the TT genotype, whereas the -834 and -921 polymorphisms failed to affect serum bFGF levels. CONCLUSIONS: We may conclude that the AT genotype of the 553 T/A polymorphism was associated with PDR in Caucasians with type 2 diabetes, therefore it might be used as a genetic marker of PDR in Caucasians, whereas carriage of the AT genotype of the -834 T/A polymorphism might decrease PDR risk.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
diabetic retinopathy  IAGP 2315844DNA:polymorphism:promotor:g.-553T>A(human)RGD 
diabetic retinopathy  ISOFGF2 (Homo sapiens)2315844; 2315844DNA:polymorphism:promotor:g.-553T>A(human)RGD 
type 2 diabetes mellitus  IEP 2315844protein:increased expression:serumRGD 
type 2 diabetes mellitus  ISOFGF2 (Homo sapiens)2315844; 2315844protein:increased expression:serumRGD 

Objects Annotated

Genes (Rattus norvegicus)
Fgf2  (fibroblast growth factor 2)

Genes (Mus musculus)
Fgf2  (fibroblast growth factor 2)

Genes (Homo sapiens)
FGF2  (fibroblast growth factor 2)


Additional Information